Alemtuzumab as first‐ and second‐line treatment in patients with Sézary syndrome—The experience of a tertiary centre

Alemtuzumab as first‐ and second‐line treatment in patients with Sézary syndrome—The experience of a tertiary centre

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology Vol. 38; no. 1; pp. e86 - e88
Main Authors: Nogueira, Miguel, Lau, Catarina, Teixeira, Maria dos Anjos, Peixeiro, Rita, Cabral, Renata, Fernandes, Iolanda
Format: Journal Article
Language:English
Published: England 01-01-2024
Subjects:
Alemtuzumab - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Humans
Sezary Syndrome - drug therapy
Skin Neoplasms - chemically induced
Skin Neoplasms - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.19441